Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
NCT00687297 · View on ClinicalTrials.gov ↗
Study Summary
It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor are formed through a process called angiogenesis. Vandetanib is an investigational drug that acts by producing what is called an anti-angiogenic effect. An Anti-angiogenic effect is able to inhibit the development of new blood vessels required by tumors to survive by blocking the growth factors needed to form new blood vessels. The purpose of this study is to determine if the addition of vandetanib to a standard chemotherapy regimen will slow or stop the growth of the cancer for a longer period of time compared to the time period generally gained from the use of standard chemotherapy alone
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Docetaxel
- DRUG vandetanib induction
- DRUG Vandetanib maintenance
Study Locations (20)
Pennsylvania
- Abington Memorial Hospital — Abington
- Hematology & Oncology of NEPA — Dunmore
- Lancaster General Hospital — Lancaster
- Central PA Hematology & Medical Oncology Associaties — Lemoyne
- University of Pennsylvania — Philadelphia
New Jersey
- Ocean Medical Center — Brick
- Morristown Memorial Hospital — Morristown
- Cancer Institute of New Jersey — New Brunswick
- Riverview Medical Center — Red Bank
Florida
- Boca Raton Community Hospital — Boca Raton
- Lakeland Regional Cancer Center — Lakeland
Michigan
- St. Joseph Mercy Hospital- Ann Arbor — Ann Arbor
- West Michigan Cancer Center — Kalamazoo
Illinois
- SwedishAmerican Hospital — Rockford
Kansas
- Cancer Center of Kansas — Wichita
Louisiana
- Ochsner Clinic — New Orleans
Maryland
- Greater Baltimore Medical Center — Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00687297
The ClinicalTrials.gov registry entry for NCT00687297 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions — of which Carboplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00687297 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Pennsylvania, New Jersey, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00687297 about?
NCT00687297 is a clinical study titled "Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer". It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor are formed through a process...
What is the current status of trial NCT00687297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2008-04. Estimated completion is 2011-04.
What conditions does trial NCT00687297 study?
This clinical trial studies the following conditions: Lung Cancer, Non Small Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00687297?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Docetaxel (DRUG), vandetanib induction (DRUG), Vandetanib maintenance (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00687297?
This trial is sponsored by PrECOG, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00687297 being conducted?
This trial has 20 study locations across Florida, Illinois, Kansas, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.